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LETTERS
Recurring Influenza 
B Virus Infections 
in Seals
To the Editor: Until 1999, 
influenza B virus was considered 
to infect humans only. However, 
more recent data proved that harbor 
seals (Phoca vitulina) and gray seals 
(Halichoerus grypus) also can be 
infected (1). Since the identification 
of seals as a novel host, antibodies 
against human influenza B viruses 
have been detected in some additional 
otarid and phocid species in a few 
relatively small studies (2,3). It has 
been speculated that seals may be an 
animal reservoir for human influenza 
B viruses, although whether influenza 
B viruses continues to circulate among 
pinnipeds is unknown.
To investigate whether influenza 
B viruses had continued to circulate in 
seals, we analyzed serum samples from 
615 seals (548 harbor seals [Phoca 
vitulina] and 67 gray seals [Halichoerus 
grypus]). The samples had been 
collected upon the animal’s admission 
to the Seal Rehabilitation and Research 
Centre (SRRC) in Pieterburen, the 
Netherlands, from seals living in Dutch 
coastal waters during 2002–2012. 
We tested these samples for influenza 
B virus–specific antibodies with a 
previously described hemagglutination 
inhbition (HI) assay, using the 
following influenza B virus strains as 
antigens: B/Seal/Netherlands/1/1999, 
B/Jiangsu/010/2003, B/Yamanashi/ 
166/1998, and B/Malaysia/2506/2004 
(4). Influenza B virus–specific 
antibodies were not detected in serum 
specimens collected from seals during 
2002–2009 and after 2011; however, 
in 2010, HI serum antibodies against 
influenza B viruses were detected in 9 
of 21 samples, and in 2011, they were 
detected in 1 of 150 samples from both 
harbor seals (n = 6) and gray seals (n = 4) 
(Figure, panel A). Nine of these positive 
samples were collected from juvenile 
seals 6–12 months of age with severe 
respiratory disease, and 1 was collected 
from a pup of ≈4 weeks of age. In seals 
>6 months of age, maternal antibodies 
have declined to undetectable levels 
(5). Therefore, these 9 juvenile seals 
must have become infected from late 
2009 through early 2010. This suggests 
that the infection was caused by the 
novel introduction of an influenza B 
virus in seals in the coastal waters of 
the Netherlands, either by seals or by 
another source. Because most serum 
samples were collected within 1 day 
of the animal’s arrival at SRRC, seals 
must have been infected in the wild and 
not at the center.
Although the 9 positive samples 
found in 2010 represent 43% of the 
tested serum samples for that year, this 
finding does not reflect the proportion 
of seropositive seals in the population. 
Only a limited number of seals of 
the population, most with respiratory 
problems, are admitted to SRRC, and 
serum is not collected from all these 
animals.
Although the 9 seropositive 
seals, all >6 months of age, had 
been admitted to SRRC with severe 
respiratory signs, it should be noted 
that severe respiratory disease in seals 
has many other causes (6). Because 
no respiratory samples suitable 
for diagnostic purposes had been 
stored, the viral agent could not be 
determined. Consequently, whether 
the influenza B virus infection of these 
seals, as evidenced by serologic test 
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Figure.	Serologic	evidence	of	 influenza	B	virus	 in	seals,	 the	Netherlands,	2002–2012.	A)	
Proportion	(prop.)	of	serum	samples	for	each	year	shown	that	were	positive	for	influenza	
B	virus	antibodies.	The	number	above	the	year	represents	the	serum	samples	tested	for	
that	year.	B)	Mean	hemagglutination	inhibition	(HI)	antibody	titers	(±SD)	of	tested	positive	
serum	samples	against	different	influenza	B	strains	belonging	to	either	the	Yamagata	(Y)	or	
Victoria	lineage	(V).	Asterisk	indicates	that	only	8	of	10	serum	samples	were	tested	against	
these	strains	because	of	the	limited	amount	of	serum	available	from	2	seals.	C)	Antigenic	
map	of	influenza	B	viruses.	Indicated	are	the	relative	positions	of	strains	(circles)	and	ferret	
antiserum	samples	(squares).	Symbols	of	strains	and	homologs	of	ferret	antiserum	samples	
are	identical,	whereas	serum	samples	of	seals	are	indicated	as	unfilled	squares.	The	spacing	
between	grid	lines	is	1	antigenic	unit,	which	corresponds	to	a	2-fold	dilution	of	antiserum	in	
the	hemagglutination	inhibition	assay.	Only	serum	samples	and	antigens	that	were	positive	
against	at	least	3	influenza	B	virus	antigens	or	serum	samples	were	included	in	the	antigenic	
map.	YT,	Yamagata;	PM,	Panama;	BE,	Beijing:	BB,	Brisbane;	HB,	Harbin;	NL,	Netherlands;	
YA,	Yamanashi;	GD,	Guandong;	MA,	Malaysia;	FL,	Florida;	JI,	Jiangsu.	A	color	version	of	
this	figure	is	available	online	(wwwnc.cdc.gov/eid/article/19/3/12-0965-F1.htm).
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results, had been symptomatic could 
not be ascertained.
To further characterize the 
influenza B virus strain that most likely 
had infected the seropositive seals, 
we tested their serum samples for 
the presence of HI antibodies against 
additional human influenza B virus 
antigens of both B/Yamagata/16/88 
and B/Victoria/2/87 lineages. These 
represent influenza B viruses that 
circulated in humans during the past 
20 years. Highest mean antibody titers 
were measured against influenza B/
Yamanashi/166/98 (mean HI titer 
781, SD 168), whereas lower antibody 
titers were detected against all other 
viruses, including influenza B/Seal/
Netherlands/1/99, which was isolated 
from seals in the Dutch coastal waters 
in 1999 (Figure, panel B). These 
results suggest that the seals had been 
infected with an influenza B virus 
similar to B/Yamanashi/166/98, which 
is antigenically different from B/Seal/
Netherlands/1/1999. 
On the basis of serum antibody 
titers against influenza B virus 
antigens tested and those of respective 
homologs of ferret antiserum samples, 
an antigenic map was prepared as 
described (7). This map, in which the 
antigenic distance between serum and 
antigen is inversely correlated with the 
HI titer, shows relative positions of the 
antigens and serum samples. Also in 
this map, tested seal serum samples 
appear to be most closely associated 
with influenza B/Yamanashi/166/98 
(Figure, panel C). The obvious 
remaining question is whether the 
influenza B virus that had infected 
these seals in 2009–2010 is a drifted 
variant of influenza B/Seal/1/99 or 
the result of another introduction of a 
human influenza B virus several years 
ago. No evidence for transmission of 
influenza B virus from seals to humans 
was found when strains circulating 
in humans in the Netherlands were 
compared with those circulating in 
seals during the observation period 
(8,9). In conclusion, results of this 
study confirm that influenza B viruses 
continue to infect seals and support 
the notion that seals could serve as 
a reservoir of human influenza B 
viruses. 
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Letters
Letters commenting on recent ar-
ticles as well as letters reporting 
cases, outbreaks, or original re-
search are welcome. Letters com-
menting on articles should contain 
no more than 300 words and 5 ref-
erences; they are more likely to 
be published if submitted within 4 
weeks of the original article’s publi-
cation. Letters reporting cases, out-
breaks, or original research should 
contain no more than 800 words 
and 10 references. They may have 1  
Figure or Table and should not be di-
vided into sections. All letters should 
contain material not previously pub-
lished and include a word count.
